{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:11:09Z","timestamp":1788012669053,"version":"build-2784847793"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR130580"],"award-info":[{"award-number":["NIHR130580"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.eclinm.2023.102213","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T06:31:57Z","timestamp":1694759517000},"page":"102213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3859-7354","authenticated-orcid":false,"given":"Georgina","family":"Nakafero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Card","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Grainge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hywel C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-212X","authenticated-orcid":false,"given":"Maarten W.","family":"Taal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3924-4830","authenticated-orcid":false,"given":"Guruprasad P.","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-9254","authenticated-orcid":false,"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian D.","family":"Mallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle A.","family":"van der Windt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-4919","authenticated-orcid":false,"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2023.102213_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102213_bib2","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102213_bib3","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"10.1016\/j.eclinm.2023.102213_bib4","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102213_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102213_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1365-2133.2011.10575.x","article-title":"British Association of Dermatologists\u2019 guidelines for the safe and effective prescribing of azathioprine 2011","volume":"165","author":"Meggitt","year":"2011","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102213_bib7","first-page":"135","article-title":"Azathioprine-induced interstitial nephritis in an anti-neutrophil cytoplasmic antibody (ANCA) myeloperoxidase (MPO) vasculitis patient","volume":"5","author":"Da Rosa","year":"2018","journal-title":"Eur J Rheumatol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102213_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2133.1993.tb00161.x","article-title":"Nephrotoxicity due to azathioprine","volume":"128","author":"McHenry","year":"1993","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102213_bib9","first-page":"807","article-title":"Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity","volume":"19","author":"Meys","year":"1992","journal-title":"J\u00a0Rheumatol"},{"issue":"9026","key":"10.1016\/j.eclinm.2023.102213_bib10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0140-6736(05)64696-X","article-title":"Acute allergic reactions associated with azathioprine","volume":"348","author":"Parnham","year":"1996","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102213_bib11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.cgh.2009.07.019","article-title":"Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations","volume":"7","author":"Lewis","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2023.102213_bib12","series-title":"British national formulary. [85]","author":"Joint Formulary Committee","year":"2023"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102213_bib13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/kew479","article-title":"BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs","volume":"56","author":"Ledingham","year":"2017","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102213_bib14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: clinical practice research datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102213_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: clinical practice research datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102213_bib16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/pds.1115","article-title":"The relationship between time since registration and measured incidence rates in the general practice research database","volume":"14","author":"Lewis","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102213_bib17","first-page":"736","article-title":"Rheumatoid arthritis is getting less frequent-results of a nationwide population-based cohort study","volume":"56","author":"Abhishek","year":"2017","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102213_bib18","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/rheumatology\/kex389","article-title":"BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs","volume":"56","author":"Ledingham","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.eclinm.2023.102213_bib19","series-title":"METHOTREXATE (oral or subcutaneous) for psoriasis and other dermatological conditions","author":"Jones","year":"2018"},{"key":"10.1016\/j.eclinm.2023.102213_bib20","series-title":"National shared care protocol: methotrexate (oral and subcutaneous) for patients in adult services (excluding cancer care)","author":"NHS England","year":"2022"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102213_bib21","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1093\/rheumatology\/keab254","article-title":"What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?","volume":"60","author":"Nakafero","year":"2021","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102213_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/kisup.2011.32","article-title":"Section 2: AKI definition","volume":"2","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102213_bib23","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1053\/j.gastro.2010.04.001","article-title":"Risk factors for idiosyncratic drug-induced liver injury","volume":"138","author":"Chalasani","year":"2010","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102213_bib24","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3899\/jrheum.200213","article-title":"Current smoking negatively affects the response to methotrexate in rheumatoid arthritis in a dose-responsive way, independently of concomitant prednisone use","volume":"48","author":"Safy-Khan","year":"2021","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102213_bib25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.crohns.2014.02.002","article-title":"Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect","volume":"8","author":"Parkes","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102213_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102393","article-title":"Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"18","author":"Parisis","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102213_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-198510040-00001","article-title":"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid","volume":"10","author":"Klotz","year":"1985","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102213_bib28","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1097\/MIB.0000000000001163","article-title":"More dose-dependent side effects with mercaptopurine over azathioprine in IBD treatment due to relatively higher dosing","volume":"23","author":"Broekman","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102213_bib29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/gut.48.5.591","article-title":"Rational dosing of azathioprine and 6-mercaptopurine","volume":"48","author":"Sandborn","year":"2001","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102213_bib30","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2036.2008.03782.x","article-title":"Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease","volume":"28","author":"Ansari","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102213_bib31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2036.2009.04221.x","article-title":"Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease","volume":"31","author":"Ansari","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102213_bib32","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.crohns.2012.02.007","article-title":"Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol","volume":"6","author":"Smith","year":"2012","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.eclinm.2023.102213_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101332","article-title":"Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): an investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial","volume":"45","author":"Kiszka-Kanowitz","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102213_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/flgastro-2016-100738","article-title":"A\u00a0practical guide to thiopurine prescribing and monitoring in IBD","volume":"9","author":"Warner","year":"2018","journal-title":"Frontline Gastroenterol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102213_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/01.MIB.0000206544.05661.9f","article-title":"5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine","volume":"12","author":"Hande","year":"2006","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102213_bib36","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/MEG.0b013e3283545ae3","article-title":"The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients","volume":"24","author":"Gao","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102213_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/FTD.0000000000000414","article-title":"Pharmacology of thiopurine therapy in inflammatory bowel disease and complete blood cell count outcomes: a 5-year database study","volume":"39","author":"Meijer","year":"2017","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102213_bib38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10067-012-2136-8","article-title":"Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy","volume":"32","author":"Dirven","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102213_bib39","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1111\/j.1572-0241.2006.00843.x","article-title":"Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients","volume":"101","author":"Gisbert","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eclinm.2023.102213_bib40","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102213_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/096228029900800102","article-title":"Multiple imputation: a primer","volume":"8","author":"Schafer","year":"1999","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.eclinm.2023.102213_bib42","series-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"Steyerberg","year":"2019"},{"key":"10.1016\/j.eclinm.2023.102213_bib43","article-title":"Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK","volume":"381","author":"Nakafero","year":"2023","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102213_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2288-13-33","article-title":"External validation of a Cox prognostic model: principles and methods","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"280","key":"10.1016\/j.eclinm.2023.102213_bib45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/01621459.1957.10501411","article-title":"Note on grouping","volume":"52","author":"Cox","year":"1957","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102213_bib46","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2023.102213_bib47","series-title":"NICE health technology evaluations: the manual","year":"2022"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102213_bib48","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/1536867X1401400403","article-title":"Tools for checking calibration of a Cox model in external validation: approach based on individual event probabilities","volume":"14","author":"Royston","year":"2014","journal-title":"Stata J"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102213_bib49","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ibd\/izx081","article-title":"Late-onset rise of 6-MMP metabolites in IBD patients on azathioprine or mercaptopurine","volume":"24","author":"Munnig-Schmidt","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102213_bib50","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1136\/gut.2006.114363","article-title":"Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine","volume":"56","author":"Vernier-Massouille","year":"2007","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102213_bib51","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.cgh.2018.05.009","article-title":"Clinical course of nodular regenerative hyperplasia in thiopurine treated inflammatory bowel disease patients","volume":"17","author":"Simsek","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102213_bib52","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/apt.14323","article-title":"Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype","volume":"46","author":"Broekman","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102213_bib53","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/apt.15458","article-title":"Increased risk of thiopurine-related adverse events in elderly patients with IBD","volume":"50","author":"Calafat","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"9261","key":"10.1016\/j.eclinm.2023.102213_bib54","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(00)04239-2","article-title":"Systemic lupus erythematosus","volume":"357","author":"Ruiz-Irastorza","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102213_bib55","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FTD.0b013e3182731925","article-title":"Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?","volume":"34","author":"Fangbin","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102213_bib56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpt.2428","article-title":"TPMT and NUDT15 variants predict discontinuation of azathioprine for myelotoxicity in patients with inflammatory disease: real-world clinical results","volume":"111","author":"Dickson","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102213_bib57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2036.2004.02124.x","article-title":"Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease","volume":"20","author":"Winter","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102213_bib58","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/FTD.0000000000001031","article-title":"Predictive algorithm for thiopurine-induced hepatotoxicity in inflammatory bowel disease patients","volume":"44","author":"van Moorsel","year":"2022","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102213_bib59","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2036.2011.04756.x","article-title":"Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients","volume":"34","author":"Gonz\u00e1lez-Lama","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102213_bib60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/ecco-jcc\/jjw130","article-title":"Early assessment of thiopurine metabolites identifies patients at risk of thiopurine-induced leukopenia in inflammatory bowel disease","volume":"11","author":"Wong","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102213_bib61","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1111\/bcp.15315","article-title":"Therapeutic drug monitoring of thiopurines: effect of reduced 6-thioguanine nucleotide target levels in inflammatory bowel disease patients","volume":"88","author":"Boekema","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102213_bib62","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10620-022-07556-y","article-title":"Proactive metabolite testing in patients on thiopurine may yield long-term clinical benefits in inflammatory bowel disease","volume":"68","author":"Barnes","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102213_bib63","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jgh.13656","article-title":"6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients","volume":"32","author":"Meijer","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102213_bib64","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/17512433.2023.2232300","article-title":"Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review","volume":"16","author":"Desai","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102213_bib65","first-page":"404","article-title":"Toxicity profile of thiopurines in inflammatory bowel disease: a retrospective cohort analysis","volume":"98","author":"Labidi","year":"2020","journal-title":"Tunis Med"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102213_bib66","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/apt.13879","article-title":"Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease","volume":"45","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102213_bib67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/gut.51.2.143","article-title":"TPMT in the treatment of Crohn's disease with azathioprine","volume":"51","author":"Lennard","year":"2002","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102213_bib68","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/gut.52.5.767","article-title":"TPMT in the treatment of inflammatory bowel disease with azathioprine","volume":"52","author":"Qasim","year":"2003","journal-title":"Gut"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023003905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:35:33Z","timestamp":1732070133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023003905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":68,"alternative-id":["S2589537023003905"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102213","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102213"}}